Edesa Biotech is trading 5.81% up at $5.01, rebounding from its August 27 decline.
- No new company-specific announcement explaining the September 1, 2026 move was identified.
- The latest notable news remains the August 19–20 public offering, which is stale relative to today’s trading and does not establish causation.
- The stock is diverging from a weaker biotech sector and broader market, suggesting a trading-driven rebound rather than a confirmed catalyst.